Neurocrine Biosciences
NBIX
NBIX
133 hedge funds and large institutions have $1.88B invested in Neurocrine Biosciences in 2014 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 44 increasing their positions, 42 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
6% more funds holding
Funds holding: 125 → 133 (+8)
5% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 42
Holders
133
Holding in Top 10
3
Calls
$20M
Puts
$17.7M
Top Buyers
| 1 | +$17.5M | |
| 2 | +$10.5M | |
| 3 | +$9.34M | |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$8.62M |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$7.7M |
Top Sellers
| 1 | -$5.73M | |
| 2 | -$5.49M | |
| 3 | -$4.51M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.26M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.92M |